Stock Analysis

SELLAS Life Sciences Group Full Year 2022 Earnings: EPS Misses Expectations

Source: Shutterstock

SELLAS Life Sciences Group (NASDAQ:SLS) Full Year 2022 Results

Key Financial Results

  • Net loss: US$41.3m (loss widened by 100% from FY 2021).
  • US$2.13 loss per share (further deteriorated from US$1.34 loss in FY 2021).
NasdaqCM:SLS Earnings and Revenue Growth March 18th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

SELLAS Life Sciences Group Earnings Insights

Looking ahead, revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.5% from a week ago.

Risk Analysis

You still need to take note of risks, for example - SELLAS Life Sciences Group has 6 warning signs (and 4 which don't sit too well with us) we think you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether SELLAS Life Sciences Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis